| Literature DB >> 31531114 |
Nur Fatin Nabilah Mohd Sahardi1, Suzana Makpol1.
Abstract
Currently, the age of the population is increasing as a result of increased life expectancy. Ageing is defined as the progressive loss of physiological integrity, which can be characterized by functional impairment and high vulnerability to various types of diseases, such as diabetes, hypertension, Alzheimer's disease (AD), Parkinson's disease (PD), and atherosclerosis. Numerous studies have reported that the presence of oxidative stress and inflammation contributes to the development of these diseases. In general, oxidative stress could induce proinflammatory cytokines and reduce cellular antioxidant capacity. Increased oxidative stress levels beyond the production of antioxidant agents cause oxidative damage to biological molecules, including DNA, protein, and carbohydrates, which affects normal cell signalling, cell growth, differentiation, and apoptosis and leads to disease pathogenesis. Since oxidative stress and inflammation contribute to these diseases, ginger (Zingiber officinale Roscoe) is one of the potential herbs that can be used to reduce the level of oxidative stress and inflammation. Ginger consists of two major active components, 6-gingerol and 6-shogaol, which are essential for preventing oxidative stress and inflammation. Thus, this paper will review the effects of ginger on ageing and degenerative diseases, including AD, PD, type 2 diabetes mellitus (DM), hypertension, and osteoarthritis.Entities:
Year: 2019 PMID: 31531114 PMCID: PMC6721508 DOI: 10.1155/2019/5054395
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Oxidative stress and inflammation in ageing and degenerative diseases [11–21].
Figure 2Chemical structures of some active compounds in ginger, Zingiber officinale Roscoe [55].
Effect of ginger on degenerative disease (in vitro studies).
| Related disease | Constituent | Effects | References |
|---|---|---|---|
| Alzheimer's disease | Ginger root extract | (i) Showed antioxidant and antiacetylcholinesterase activity | Tung et al. [ |
| 6-Gingerol | (i) Suppressed the expression of | Lee et al. [ | |
|
| |||
| Parkinson's disease | 6-Shogaol | (i) Protected dopaminergic neurons against MPTP- and MPP+-induced neurotoxicity | Park et al. [ |
| 6-Shogaol | (i) Inhibited the release of NO and the expression of inducible nitric oxide synthase (iNOS) | Ha et al. [ | |
|
| |||
| Type 2 diabetes mellitus | Ginger extract | (i) Exhibited strong antioxidant activities | Oboh et al. [ |
|
| |||
| Cardiovascular disease | Ginger extract | (i) Induced the relaxation of coronary arteries | Wu et al. [ |
Effect of ginger on degenerative disease (in vivo studies).
| Related Disease | Constituent | Effects | References |
|---|---|---|---|
| Alzheimer's disease | Ginger root extract | (i) Improved learning and memory | Zeng et al. [ |
| Aqueous ginger infusion | (i) Improved the activity and level of acetylcholine | Karam et al. [ | |
|
| |||
| Parkinson's disease | 6-Shogaol | (i) Reduced astrogliosis and microgliosis in the brain | Moon et al. [ |
| 6-Shogaol | (i) Improved the formation of synapses in the brain | Park et al. [ | |
|
| |||
| Type 2 diabetes mellitus | Fresh ginger sample | (i) Exhibited inhibitory activities against | Akinyemi et al. [ |
|
| |||
| Cardiovascular disease | Ginger extract | (i) Reduced infarct size | Rouhi-Boroujeni et al. [ |
| Ethanolic ginger extract | (i) Decreased the development of atherosclerotic lesions | Fuhrman et al. [ | |
| 6-Gingerol | (i) Reduced atherosclerotic lesions in arteries | Wang et al. [ | |
| Dried ginger powder | (i) Decreased lipid levels and blood pressure | Sanghal et al. [ | |
| Aqueous ginger extract | (i) Inhibited ACE activity | Akinyemi et al. [ | |
| Fresh ginger sample | (i) Inhibited ACE activity | Akinyemi et al. [ | |
Effect of ginger on degenerative disease (human studies).
| Related disease | Constituent | Effects | References |
|---|---|---|---|
| Type 2 diabetes mellitus | Fresh ginger rhizomes | (i) Reduced the levels of triglycerides (TG) and low-density lipoprotein (LDL) | Mahluji et al. [ |
| Powdered ginger rhizomes | (i) Decreased TG level and total serum cholesterol | Arablou et al. [ | |
| Powdered ginger capsule | (i) Decreased the levels of glucose, malondialdehyde (MDA), and C-reactive protein (CRP) and insulin resistance | Shidfar et al. [ | |
|
| |||
| Osteoarthritis | Powdered ginger capsule | (i) Decreased the level of tumour necrosis alpha (TNF- | Mozaffari-khosravi et al. [ |
| Powdered ginger capsule | (i) Reduced the level of nitrite oxide (NO) | Naderi et al. [ | |
| Powdered ginger capsule | (i) Reduced stiffness, pain, and difficulty in patients with knee osteoarthritis | Zakeri et al. [ | |
|
| |||
| Cardiovascular disease | Powdered ginger capsule | (i) Reduced blood pressure in patients with hypertension and coronary heart disease | Wang et al. [ |